Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Cytokinetics stops developing tirasemtiv after failed late-stage ALS study; trading halted
Cytokinetics (NASDAQ.
FDA approves Cipla’s generic Pulmicort Respules
The Food and Drug Administration has approved Cipla’s generic of AstraZeneca's Pulmicort Respules (budesonide inhalation suspension).
Ajanta launches generic Kapvay
Ajanta Pharma has launched its generic of Concordia Pharmaceuticals’ Kapvay (clonidine hydrochloride) extended-release tablets.
FDA approves Glenmark’s generic Hailey Fe 1/20
The Food and Drug Administration has approved Glenmark Pharmaceuticals’ generic of Allergan’s Hailey Fe 1/20 norethindrone acetate, 1 mg, and ethinyl estradiol, 20 mcg) tablets.
Teva to Cut Up to 25% of Israel Workforce, Calcalist Says
Teva Pharmaceutical Industries Ltd.
Janssen’s Zytiga approved for earlier use in prostate cancer
European regulators are allowing earlier use of Janssen’s Zytiga in the treatment pathway for metastatic prostate cancer.
Acorda drops experimental Parkinson’s drug
US biotech Acorda Therapeutics is discontinuing development of its experimental Parkinson’s disease therapy tozadenant on concerns over patient safety.
EU approves post-chemo option for patients with ovarian cancer
European regulators have cleared Tesaro’s Zejula, offering a new option for the maintenance treatment of certain adults with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopi...
FDA approves first two-drug regimen for certain patients with HIV
The U.
Medicare Part D rule change would be another win for pharma’s lobbyists, analyst says
Pharma stands to win again in Washington, D.
Allergan could sell women's health for $6B, if it would only agree to split: analyst
RBC Capital Markets analyst Randall Stanicky sees lots of reasons Allergan should pursue a breakup.
Alnylam set to speed patisiran development with Breakthrough designation
The US Food and Drug Administration has granted Breakthrough Therapy designation (BTD) for patisiran, an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatmen...
522
523
524
525
526
527
528
529
530
